Already a member or subscriber? Sign in now

Saving Lives Through QI: Improving Blood Pressure Control in Primary Care

MARK SHAFFER, MD
EMILY RIDLEY, PharmD
STACEY HASTINGS
TISHA BOSTON, MD
SIDNEY EARLEY

FPM. 2025;32(3):11-16.

Author disclosures: no relevant financial affiliations.

Tools: Hypertension protocol and algorithm for pharmacotherapy advancement

An organized approach to quality improvement, with active physician engagement, led to an estimated 130 lives saved at 10 offices. Here's how they did it.

The prevalence of hypertension in the United States is staggering, with almost half of adults (119.9 million) meeting the American Heart Association's criteria for the condition — blood pressure (BP) ≥ 130/80 mm Hg or current use of medication to lower BP.1 Only about one-fourth of those (27 million) have their hypertension under control.1 Lowering BP significantly reduces cardiovascular (CV) events, stroke, and death with an absolute risk reduction of 28 CV events, 17 strokes, and nine deaths per 1,000 persons treated for five years.2

Due to its profound impact on outcomes, hypertension control is often a target for quality improvement (QI) and pay-for-performance programs. In 2021, our health care system was linking patient panel outcomes on certain quality measures, including hypertension control, to clinician performance pay. Unfortunately, many clinicians were skeptical of data accuracy and patient attribution, and they did not want to be held accountable for factors they could not control, such as medication adherence or measurements obtained in a different setting (e.g., the emergency department). In part because of these barriers, physician engagement in QI efforts was low across our 10 family medicine offices. Our rates of hypertension control were under target, and our approach to improvement was not yielding the desired results.

Recognizing the need for change, we began with the basics of quality improvement — identifying key drivers of hypertension control, developing a protocol with clear roles, defining leading measures, and rewarding our clinicians based on metrics they could understand and influence. After two years of sustained effort, we increased the absolute rate of BP control in our 10-practice family medicine department by 7.5%, to 78%. This exceeded the HEDIS top decile of 75.22% and translated to 1,445 more patients at goal. Using the conservative estimate of one death prevented for every 11 patients at goal over 10 years,3 this means about 130 lives would be saved over the next decade. (See the results.)

We are sharing our experience as a model for other practices to consider when implementing QI work around hypertension and evaluating quality performance incentives.

KEY POINTS

  • Hypertension QI efforts should focus on key drivers of BP control such as BP measurement accuracy, timely follow up, and more aggressive advancement of pharmacotherapy.
  • To ensure the team is on the same page, develop a protocol that clarifies the process or expectation for each of the key drivers (e.g., follow up with the patient within six weeks after an elevated BP).
  • Build an incentive plan based on leading (process) metrics that clinicians can influence, not just lagging (outcome) metrics.

Dr. Shaffer is vice chair of quality and medical affairs and clinical associate professor, Department of Family and Preventive Medicine, University of South Carolina (USC) School of Medicine/Prisma Health, Columbia, S.C.

Dr. Ridley is with the Department of Pharmacy, Prisma Health, is a clinical instructor of internal medicine, Department of Internal Medicine, USC School of Medicine, and is a clinical assistant professor (academic affiliate), Department of Clinical Pharmacy and Outcome Sciences, USC College of Pharmacy.

Stacey Hastings is manager of ambulatory quality, inVio Health Network.

Dr. Boston is vice chair of clinical operations and clinical assistant professor, Department of Family and Preventive Medicine, USC School of Medicine/Prisma Health.

Sidney Earley is an MHA candidate at USC.

Send comments to fpmedit@aafp.org, or add your comments to the article online.

Author disclosures: no relevant financial affiliations.

  1. 1.Estimated hypertension prevalence, treatment, and control among U.S. adults. Million Hearts/Centers for Disease Control and Prevention. May 12, 2023. Accessed March 31, 2025. https://millionhearts.hhs.gov/data-reports/hypertension-prevalence.html
  2. 2.Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32(12):2285-2295.
  3. 3.Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension. 2000;35(2):539-543.
  4. 4.Roerecke M, Kaczorowski J, Myers MG. Comparing automated office blood pressure readings with other methods of blood pressure measurement for identifying patients with possible hypertension: a systematic review and meta-analysis. JAMA Intern Med. 2019;179(3):351-362.
  5. 5.Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47(3):345-351.
  6. 6.Hanlin RB, Asif IM, Wozniak G, et al. Measure Accurately, Act Rapidly, and Partner With Patients (MAP) improves hypertension control in medically underserved patients: Care Coordination Institute and American Medical Association Hypertension Control Project Pilot Study results. J Clin Hypertens (Greenwich). 2018;20(1):79-87.
  7. 7.HEARTS: Technical package for cardiovascular disease management in primary health care: implementation guide. World Health Organization; 2018. https://apps.who.int/iris/bitstream/handle/10665/275728/WHO-NMH-NVI-18.14-eng.pdf

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.